Media Coverage | Endeavor BioMedicines

October 8, 2026

Endeavor’s threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitor

September 16, 2026

Taladegib Improves Lung Fibrosis on Quantitative CT: Peter George, MBBS, PhD

June 26, 2026

While inhibiting the Hedgehog signaling pathway has typically been used in oncology, San Diego based Endeavor BioMedicines has one they believe is well suited for fibrotic diseases like IPF

November 12, 2025

ENV-101 shown to improve lung function in early IPF trial

October 22, 2025

From Slowing Decline to Restoring Function: Taladegib’s Promise in IPF, With Toby Maher, MD, PhD

June 26, 2025

Deep Learning Biomarkers Help Uncover ENV-101 Treatment Effects in IPF

April, 2025

How One Aggie Is Transforming Cancer Treatment

Clinical Trials Arena

November 21, 2024

Endeavor Doses First Subject in Phase IIb Trial of ENV-101 for IPF Treatment

August 27, 2024

What Will it Take to Solve the Devastating Riddle of Idiopathic Pulmonary Fibrosis?

June 7, 2024

Study: ENV-101 Improves IPF Lung Function, Reverses Fibrosis

May 20, 2024

Taking on Pharma Giants, Endeavor Links IPF Drug to Improved Lung Function in Phase 2

April 26, 2024

John Hood on Endeavor’s $132.5M Series C and Hedgehog Inhibition for IPF

April 24, 2024

Endeavor BioMedicines Snags $132M for Phase 2 Fibrosis Drug, ADC Candidate

September 24, 2021

1st Patient Dosed in Trial of IPF Therapy Candidate Taladegib

January 7, 2021

Endeavor BioMedicines Raises $62 Million to Combat Pulmonary Disease

January 7, 2021

Endeavor Launches with $62m and a Hedgehog Inhibitor from Lilly

January 7, 2021

Serial Biotech Entrepreneur John Hood Raises $62 Million for Company Aimed at Deadly Lung Disease

January 7, 2021

My Newest Puzzle, Endeavor BioMedicines, and the Chance to Reverse a Devastating Pulmonary Disease